MSD’s Noxafil Price to Be Trimmed 0.5% under CEA Scheme

MSD’s antifungal agent Noxafil (posaconazole) will get a price cut of 0.5% based on its cost-effectiveness assessment (CEA), a Japanese reimbursement policy panel agreed on November 17. The price reduction will take effect on February 1. The Central Social Insurance...read more